CCL2 and obesity disorder: In obesity, WAT releases pro-inflammatory adipokines, such as tumor necrosis factor (TNF)-α, plasminogen activator inhibitor (PAI)-1, and monocyte chemoattractant protein (MCP)-1, which impair glucose metabolism due to the induction of low-grade systemic inflammation [10].